Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
UnitedHealth Group Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Dividend Discount Model (DDM)
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to UnitedHealth Group Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity profile exhibits a consistent pattern of current liabilities exceeding current assets, with ratios remaining below 1.0 throughout the analyzed period. While there were temporary improvements in overall liquidity during 2024, a long-term contraction in immediate cash availability is evident.
- Current Ratio
- The current ratio fluctuated within a narrow range between 0.77 and 0.85 for much of the period, before reaching a peak of 0.91 on September 30, 2024. Following this peak, the ratio retracted to 0.79 by December 31, 2024, eventually stabilizing at 0.80 by March 31, 2026.
- Quick Ratio
- The quick ratio closely mirrored the movements of the current ratio, ranging from a low of 0.70 to a peak of 0.83 in September 2024. The minimal variance between the current and quick ratios suggests that inventory levels do not significantly impact the overall liquidity position.
- Cash Ratio
- A sustained downward trend is observed in the cash ratio. After reaching a high of 0.46 on September 30, 2022, the ratio progressively declined, hitting a low of 0.24 on December 31, 2025. This indicates a reduction in the proportion of highly liquid cash assets available to cover short-term obligations.
The convergence of the current and quick ratios, coupled with the steady decline of the cash ratio, suggests a shift in asset composition or an increase in the utilization of cash reserves. Despite a brief recovery in liquidity during the third quarter of 2024, the organization maintained a liquidity position characterized by a dependency on non-cash current assets or operational cash flow to meet immediate liabilities.
Current Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity profile is characterized by a consistent pattern where current liabilities exceed current assets, resulting in a current ratio that remains below 1.0 across all reported periods. Despite this deficit, a gradual improvement in the liquidity position is observed through late 2024, followed by a period of relative stabilization through early 2026.
- Current Ratio Trends
- The current ratio fluctuated within a narrow band, ranging from a minimum of 0.77 in June 2022 to a peak of 0.91 in September 2024. A notable period of strengthening occurred throughout 2024, during which the ratio climbed from 0.83 in December 2023 to its peak of 0.91, before moderating back to 0.80 by March 2026.
- Asset and Liability Correlation
- Current assets and current liabilities exhibit a strong positive correlation, moving in tandem over the analyzed timeframe. For example, a significant increase in current assets to US$ 93,895 million in March 2023 was mirrored by a peak in current liabilities of US$ 116,482 million. This suggests that fluctuations in liquidity are primarily driven by the proportional scaling of short-term operational requirements and obligations.
- Short-Term Solvency Observations
- Although the current ratio consistently remains below the 1.0 threshold, the stability of the ratio between 0.77 and 0.91 indicates a managed approach to working capital. The absence of sharp declines suggests that the entity maintains a predictable relationship between its short-term assets and its immediate obligations, avoiding significant volatility in its liquidity coverage.
Quick Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||
| Other current receivables, net | |||||||||||||||||||||||
| Assets under management | |||||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of liquidity indicators between March 2022 and March 2026 reveals a consistent pattern of operating with a quick ratio below 1.0, indicating that quick assets are insufficient to cover total current liabilities on a standalone basis. Despite this, the ratio demonstrates relative stability, fluctuating within a narrow range between 0.70 and 0.83.
- Total Quick Assets Trend
- Quick assets exhibited notable volatility, beginning at 63,416 million US dollars in March 2022 and reaching an initial peak of 87,444 million US dollars in March 2023. Following a decline to 72,353 million US dollars by December 2023, assets recovered to a secondary peak of 87,249 million US dollars in March 2025, before ending the period at 82,404 million US dollars in March 2026.
- Current Liabilities Movement
- Current liabilities generally moved in tandem with quick assets, peaking in March 2023 at 116,482 million US dollars. A period of relative contraction was observed between December 2023 and September 2024, during which liabilities decreased to a low of 101,565 million US dollars. By March 2026, these obligations had increased again to 114,124 million US dollars.
- Quick Ratio Analysis
- The quick ratio remained largely stable, with a minimum value of 0.70 recorded in December 2022 and December 2025. A positive trend in liquidity was observed throughout 2024, resulting in a peak ratio of 0.83 in September 2024. This peak was driven by a combination of stable quick assets and a temporary reduction in current liabilities. Subsequent to this period, the ratio experienced a gradual decline, returning to 0.72 by March 2026.
Cash Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||||
| Assets under management | |||||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibits a general downward trajectory over the analyzed period, characterized by initial volatility between 2022 and 2023 followed by a sustained decline through 2025. This trend indicates a reduction in the proportion of most liquid assets available to cover immediate short-term obligations.
- Cash Asset Dynamics
- Total cash assets experienced significant fluctuations, peaking at US$ 50,334 million in March 2023. Following this peak, a gradual contraction is observed, with cash levels descending to a low of US$ 28,121 million in December 2025 before a slight recovery to US$ 31,229 million by March 2026.
- Current Liability Trends
- Current liabilities maintained a generally upward trend, rising from US$ 88,170 million in March 2022 to peak at US$ 116,482 million in March 2023. In the latter half of the period, liabilities remained elevated, consistently exceeding US$ 100,000 million from March 2024 through March 2026, which intensified the downward pressure on the liquidity ratio.
- Cash Ratio Analysis
- The cash ratio reached its maximum value of 0.46 in September 2022. A period of relative stability was maintained between 0.34 and 0.44 through December 2023. However, from March 2024 onward, a consistent erosion of the ratio is evident, falling to a minimum of 0.24 in December 2025. This decline is primarily driven by the simultaneous decrease in total cash assets and the persistence of high current liabilities.
- Liquidity Observations
- The contraction of the cash ratio from 0.46 to 0.27 over the observed timeframe suggests a shift in the liquidity profile. While a marginal uptick occurred in March 2026, the overall trend reflects a diminished capacity to settle current liabilities using only cash and cash equivalents compared to the position held in 2022.